Abstract：【Objective】 To investigate the effects of levothyroxine sodium combined with clozapine on nerve-related factors (PSA-NCAM: polysialic acid nerve cell adhesion molecules, MBP: myelin basic protein and NSE: neuron specific enolase) in patients with schizophrenia. 【Methods】 A total of 118 patients with schizophrenia in our hospital from January 2018 to October 2019 were selected and divided into two groups with a random number table, with 59 cases in each group. The control group was given clozapine alone, and the observation group was given levothyroxine sodium + clozapine for 6 weeks of continuous treatment. The treatment effects and adverse reactions of the two groups were counted, nerve-related factors (PSA-NCAM, MBP, NSE), thyroid hormone [free triiodothyronine (FT3), free tetraiodothyronine (FT4), thyroid-stimulating hormone (TSH)]. 【Results】 The total effective rate of the observation group was 91.53%, which was higher than that of the control group (76.27%, P<0.05). Serum PSA-NCAM, MBP and NSE in the observation group were lower than those in the control group after 6 weeks of treatment (P<0.05). Serum FT3 and FT4 of the observation group were higher than those of the control group after 6 weeks of treatment (P<0.05). There was no significant difference in serum TSH levels between the two groups after 3 and 6 weeks of treatment (P>0.05). The incidence of dry mouth, constipation, weight gain, tachycardia, and menstrual disorders in the observation group was not statistically different from that in the control group (P>0.05). 【Conclusion】 The combination of levothyroxine sodium and clozapine has a significant effect on the treatment of schizophrenia, which helps to regulate the levels of serum PSA-NCAM, MBP, NSE, FT3, FT4, control agitation behavior, improve sleep quality, improve cognitive function, and has high safety.
刘淼, 刘磊, 王圣海. 氯氮平联合左甲状腺素钠治疗精神分裂症的疗效及对神经相关因子水平的影响[J]. 医学临床研究, 2021, 38(4): 583-585.
LIU Miao, LIU Lei, WANG Sheng-hai. Effect of Levothyroxine Sodium Combined with Clozapine on Nerve-related Factors in Patients with Schizophrenia. JOURNAL OF CLINICAL RESEARCH, 2021, 38(4): 583-585.
[1] MARIC N P, JOVICIC M J, MIHALJEVIC M,et al. Improving current treatments for schizophrenia[J].Drug Dev Res,2016,77(7):357-367. [2] OTA V K,NOTO C,SANTORO M L,et al.Increased expression of ndel1 and mbp genes in the peripheral blood of antipsychotic-naive patients with first-episode psychosis[J].Eur Neuropsychopharmacol,2015,25(12):2416-2425. [3] VAREA E,GUIRADO R,GILABERT-JUAN J,et al.Expression of psa-ncam and synaptic proteins in the amygdala of psychiatric disorder patients[J].J Psychiatr Res,2012,46(2):189-197. [4] 段侠霞,张燕,张盟,等.非典型抗精神病药对儿童青少年精神分裂症血清甲状腺激素和血脂的影响[J].中国医药导报,2019,16(5):151-154. [5] 张艺,郭春锋.不同抗精神病药物对精神分裂症患者心电图的影响[J].安徽医学,2018,39(2):193-195. [6] 郝伟,于欣.精神病学[M].第7版.北京:人民卫生出版社,2013:93-108. [7] 肖文焕,陈宽玉,叶飞,等.奥氮平对精神分裂症患者血清血管内皮生长因子水平的影响及其与临床疗效的关系[J].神经疾病与精神卫生,2018,18(9):646-649. [8] LALLY J,MALOUDI S,KRIVOY A,et al.Simple schizophrenia:a forgotten diagnosis in psychiatry[J].J Nerv Ment Dis,2019,207(9):721-725. [9] 路钊,贺静,陈英,等.精神分裂症患者氯氮平血药浓度与血清同型半胱氨酸水平的相关性[J].中国神经精神疾病杂志,2019,45(10):602-606. [10] 王俊,杜云红,刘建萍,等.齐拉西酮片联合氯氮平治疗难治性精神分裂症疗效及对认知功能的影响[J].国际精神病学杂志,2019,46(2):260-262. [11] 张誉洋,何丽,王艺鹏,等.左甲状腺素钠对CHF伴亚临床甲减患者血清甲状腺激素和炎症因子水平及LVEF影响[J].陕西医学杂志,2018,47(1):69-71. [12] 杨明杰.精神分裂症患者血清蛋白因子水平的表达特点及其意义[J].解放军预防医学杂志,2018,36(9):1207-1210. [13] SATO C,HANE M.Mental disorders and an acidic glycan-from the perspective of polysialic acid (psa/polysia) and the synthesizing enzyme,ST8SIA2[J].Glycoconj J,2018,35(4):353-373. [14] 王志敏,陈平,林晓东,等.奥氮平和氯氮平对男性精神分裂症病人甲状腺激素的影响及相关因素分析[J].青岛大学医学院学报,2018,54(6):714-717.
2021, Vol. 38 
